Hikma Pharmaceuticals PLC (“Hikma”) has announced its interim results for the six months ended 30 June 2014, Zawya reported. Group revenue increased by 16% to $738m, driven by the strong performance of the Injectables business. Hikma continued to build its global product portfolio by introducing new products to its markets. A total of 49 products were launched and 140 product approvals were received in the first half of 2014. Mr. Said Darwazah, Chief Executive Officer of Hikma, said, “I am very pleased with our first half results, which reflect strong underlying performance in our businesses and our success in capturing a number of specific market opportunities. In the MENA region, our focus on new, higher value products is delivering strong results in key markets. Our Injectables business delivered an excellent performance, as we captured a number of attractive market opportunities.” Hikma contributes to developing communities in areas where it works and improving the quality of life. It supports sustainable initiatives and encourages its employees to volunteer.
Sunday, August 24- 2014 @ 0:34 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.